Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
about
Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort.Systematic synergy modeling: understanding drug synergy from a systems biology perspective.Estimating the number of sudden cardiac deaths attributable to the use of domperidone in France.The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.Drug use in French children: a population-based study.Impact of clinical characteristics and management on the prognosis of unselected heart failure patients.Usage patterns of paracetamol in France.Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database.Trends in the incidence of use of noninsulin glucose-lowering drugs between 2006 and 2013 in France.Nonadherence in the Learning Healthcare System: Avoiding a Mountain by Seeing the Bumps.Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting.
P2860
Q30881762-A9E2C1DF-B110-4A91-A79F-34B1EC760538Q35777950-87B7B8A8-0E16-475E-832E-86BEF81C6FEFQ38400100-6B3C3A46-3316-4E4D-A265-1F753FEE604CQ38764020-5BB76B68-F978-46E7-B0DA-1F864602B948Q38998154-D8D8E9D9-A110-4A13-A0A4-72287D014EB8Q39882062-2009A7F3-A4DB-4AA7-819A-86249ECFB8C5Q40272818-422659A2-1AC0-4673-926A-5A6D1D8680D1Q40936661-65A81502-96B3-481C-95C3-4450F72EAA3EQ41381001-2CD31A11-3662-4A4F-AA16-C34A201F37ACQ42382870-C963691A-7082-48AC-8D74-5B195C47E30AQ47237796-091CE3F6-5ABB-45AB-9BB0-C82D0A93E705Q48334652-8D7E725C-FE85-448F-BE95-0407CFF9D40BQ50095853-0BC74ABB-65C8-4603-B96F-B971B0022BBFQ50217749-E769991D-DE7C-4800-BC8F-6DBA8AA9B35C
P2860
Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Use of the recommended drug co ...... e coronary syndrome in France.
@en
Use of the recommended drug co ...... e coronary syndrome in France.
@nl
type
label
Use of the recommended drug co ...... e coronary syndrome in France.
@en
Use of the recommended drug co ...... e coronary syndrome in France.
@nl
prefLabel
Use of the recommended drug co ...... e coronary syndrome in France.
@en
Use of the recommended drug co ...... e coronary syndrome in France.
@nl
P2093
P2860
P1476
Use of the recommended drug co ...... te coronary syndrome in France
@en
P2093
A Abouelfath
A Fourrier-Reglat
A Pariente
C Droz-Perroteau
C Dureau-Pournin
P Robinson
R Lassalle
P2860
P2888
P304
P356
10.1007/S00228-013-1614-5
P577
2013-11-24T00:00:00Z
P5875
P6179
1016119485